These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

749 related items for PubMed ID: 25501326

  • 21. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM, Soriano Castrejón A, Cruz Mora MÁ, Ortega Ruiperez C, Espinosa Aunión R, León Martín A, González Ageitos A, Van Gómez López O.
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
    [Abstract] [Full Text] [Related]

  • 22. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J, Wang Y, Mo M, Bao X, Zhang Y, Liu G, Zhang J, Geng D.
    Oncotarget; 2015 Oct 06; 6(30):29388-95. PubMed ID: 26336821
    [Abstract] [Full Text] [Related]

  • 23. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S, Yoshizawa N, Shigekawa T, Takeuchi H, Ogura H, Osaki A, Saeki T, Ueda Y, Yamane T, Kuji I, Sakahara H.
    J Nucl Med; 2016 Aug 06; 57(8):1189-95. PubMed ID: 26940765
    [Abstract] [Full Text] [Related]

  • 24. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM, Rani SD, Li X, Arlinghaus LR, Lee TC, MacDonald LR, Partridge SC, Kang H, Whisenant JG, Abramson RG, Linden HM, Kinahan PE, Yankeelov TE.
    Med Phys; 2015 Jul 06; 42(7):3801-13. PubMed ID: 26133582
    [Abstract] [Full Text] [Related]

  • 25. Whole-body 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) for staging locally advanced breast cancer: A prospective study from a tertiary cancer centre in south India.
    Gajjala SR, Hulikal N, Kadiyala S, Kottu R, Kalawat T.
    Indian J Med Res; 2018 Mar 06; 147(3):256-262. PubMed ID: 29923514
    [Abstract] [Full Text] [Related]

  • 26. 18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.
    Groheux D, Martineau A, Teixeira L, Espié M, de Cremoux P, Bertheau P, Merlet P, Lemarignier C.
    Breast Cancer Res; 2017 Jan 05; 19(1):3. PubMed ID: 28057031
    [Abstract] [Full Text] [Related]

  • 27. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.
    Koolen BB, Donker M, Straver ME, van der Noordaa MEM, Rutgers EJT, Valdés Olmos RA, Vrancken Peeters MJTFD.
    Br J Surg; 2017 Aug 05; 104(9):1188-1196. PubMed ID: 28524246
    [Abstract] [Full Text] [Related]

  • 28. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J, Zhou Z, Yang Z, Chen X, Cheng J, Shao Z, Guo X, Tuan J, Fu X, Yu X.
    Medicine (Baltimore); 2016 Feb 05; 95(8):e2914. PubMed ID: 26937935
    [Abstract] [Full Text] [Related]

  • 29. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ.
    Breast Cancer; 2013 Apr 05; 20(2):167-73. PubMed ID: 22311581
    [Abstract] [Full Text] [Related]

  • 30. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, Iagaru A.
    J Nucl Med; 2015 Dec 05; 56(12):1862-8. PubMed ID: 26405167
    [Abstract] [Full Text] [Related]

  • 31. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, Kimmig KR, Forsting M, Bockisch A, Antoch G.
    J Nucl Med; 2008 Aug 05; 49(8):1215-22. PubMed ID: 18632831
    [Abstract] [Full Text] [Related]

  • 32. Subtype-Guided 18 F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.
    Wu S, Wang Y, Li J, Zhang N, Mo M, Klimberg S, Kaklamani V, Cochet A, Shao Z, Cheng J, Liu G.
    Oncologist; 2020 Apr 05; 25(4):e626-e633. PubMed ID: 32297448
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D, Majdoub M, Sanna A, de Cremoux P, Hindié E, Giacchetti S, Martineau A, de Roquancourt A, Merlet P, Visvikis D, Resche-Rigon M, Hatt M, Espié M.
    Radiology; 2015 Nov 05; 277(2):358-71. PubMed ID: 25915099
    [Abstract] [Full Text] [Related]

  • 36. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
    Schmitz AMT, Teixeira SC, Pengel KE, Loo CE, Vogel WV, Wesseling J, Rutgers EJT, Valdés Olmos RA, Sonke GS, Rodenhuis S, Vrancken Peeters MJTFD, Gilhuijs KGA.
    PLoS One; 2017 Nov 05; 12(5):e0176782. PubMed ID: 28531188
    [Abstract] [Full Text] [Related]

  • 37. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, Espié M.
    Eur J Cancer; 2014 Jul 05; 50(11):1864-71. PubMed ID: 24841218
    [Abstract] [Full Text] [Related]

  • 38. Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.
    van Ramshorst MS, Teixeira SC, Koolen BB, Pengel KE, Gilhuijs KG, Wesseling J, Rodenhuis S, Valdés Olmos RA, Rutgers EJ, Vogel WV, Sonke GS, Vrancken Peeters MT.
    Cancer Imaging; 2017 May 25; 17(1):15. PubMed ID: 28545563
    [Abstract] [Full Text] [Related]

  • 39. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
    Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Moriya T, Yamamoto J.
    Breast Cancer; 2011 Oct 25; 18(4):299-308. PubMed ID: 20617404
    [Abstract] [Full Text] [Related]

  • 40. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy.
    Kim SJ, Kim SK, Lee ES, Ro J, Kang Sh.
    Ann Oncol; 2004 Sep 25; 15(9):1352-7. PubMed ID: 15319241
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.